Having trouble accessing articles? Reset your cache.

Brii continues to grow infectious disease pipeline via deal with start-up AN2

Brii has added tuberculosis to its fast-growing infectious disease portfolio via a deal with start-up AN2, which emerged from stealth Thursday with a $12 million series A round.

Mountain Group Partners led the round

Read the full 331 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE